JG
GANX icon

Joel Greenblatt’s Gain Therapeutics GANX Stock Holding History

Joel Greenblatt’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-245,896
Closed -$5.36M – 1738
2025
Q2 		$5.36M Buy
245,896
+91,912
+60% +$170K 0.03% 645
2025
Q1 		$3.17M Sell
153,984
-4,171
-3% -$9.25K 0.03% 654
2024
Q4 		$3.74M Sell
158,155
-176,437
-53% -$354K 0.04% 582
2024
Q3 		$7.38M Buy
+334,592
New +$421K 0.08% 382

Other funds holding GANX

Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Joel Greenblatt's GANX Position: Q3 2025 in Review

Joel Greenblatt sold out of Gain Therapeutics (GANX) in Q3 2025, closing a stake of 245,896 shares — an estimated $5.36M sold.

Joel Greenblatt first reported a position in GANX in Q3 2024 and held it in 4 quarters. The position peaked at $7.38M in Q3 2024. 38 funds tracked by Wall St. Rank hold GANX as of Q3 2025.

  • Joel Greenblatt reported no remaining Gain Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Joel Greenblatt sold 245,896 Gain Therapeutics shares in Q3 2025, an estimated $5.36M.
  • Joel Greenblatt first reported a position in Gain Therapeutics in Q3 2024 and held it in 4 quarters.
  • Joel Greenblatt's Gain Therapeutics position peaked at $7.38M in Q3 2024.
  • 38 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2025.

Based on Gotham Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.